Please check your internet connection and try again.
## Clobazam (Oral)
### Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties.
### Primary Indications
Adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric and adult patients.
### Adult Dosing
* **Initial:** 5 mg twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week based on clinical response and tolerability.
* **Maintenance:** Typically 10 mg to 20 mg twice daily.
* **Maximum:** 20 mg twice daily (40 mg/day). Some sources may indicate higher maximums for specific refractory epilepsy cases, but generally adhere to the 40 mg/day maximum.
### Pediatric Dosing (LGS)
* **Age 2 to <10 years:**
* **Initial:** 5 mg once daily.
* **Titration:** Increase dose by 2.5 mg to 5 mg every week based on clinical response and tolerability.
* **Maintenance:** Typically 5 mg to 10 mg twice daily.
* **Maximum:** 10 mg twice daily (20 mg/day).
* **Age 10 years and older:** Dosing is the same as adults.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution; no specific dose adjustment is established, but lower doses may be warranted due to potential accumulation.
* **Renal Impairment:** Use with caution; no specific dose adjustment is established.
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
### Adverse Effects
* **Common:** Somnolence, decreased appetite, aggression, ataxia, irritability, vomiting, constipation, difficulty walking, fatigue, upper respiratory tract infection.
* **Serious:** Suicidal ideation/behavior, severe somnolence, withdrawal symptoms (including seizures), Stevens-Johnson syndrome, toxic epidermal necrolysis.
### Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Additive CNS depression; use caution and consider dose reduction of one or both agents.
* **CYP2C19 Inhibitors (e.g., fluconazole, omeprazole):** May increase clobazam concentrations; monitor for increased adverse effects.
* **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam concentrations.
* **CNS Stimulants:** Clobazam may decrease the efficacy of certain stimulants.
### Monitoring
* **Efficacy:** Assess seizure frequency and severity.
* **Safety:** Monitor for somnolence, ataxia, behavioral changes, suicidal ideation, and signs of withdrawal.
* **Drug Interactions:** Be aware of potential interactions with other CNS depressants or drugs affecting CYP2C19.
### Clinical Pearls
* Clobazam is generally considered less sedating than other benzodiazepines, but somnolence is still a common adverse effect.
* Slow titration is crucial to minimize adverse effects and optimize efficacy.
* Abrupt discontinuation can lead to withdrawal symptoms, including seizures. Taper slowly.
* Clobazam is metabolized by CYP2C19. Genetic variability in CYP2C19 can affect clobazam pharmacokinetics.
***
*This information is intended for clinical use and does not replace the manufacturer's full prescribing information or local protocols. Always verify current prescribing information before use.*
